Axatilimab (SNDX-6352)

DRUG2 trials

Sponsors

M.D. Anderson Cancer Center

Conditions

Breast CancerChronic Myelomonocytic Leukemia (CMML)Myelofibrosis (MF)

Phase 1

A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC)

RecruitingNCT06959537

M.D. Anderson Cancer CenterBreast Cancer

Start: 2025-08-13End: 2029-01-31Target: 24Updated: 2026-07-30

Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)

RecruitingNCT07128381

M.D. Anderson Cancer CenterChronic Myelomonocytic Leukemia (CMML), Myelofibrosis (MF)

Start: 2026-01-02End: 2033-07-31Target: 66Updated: 2026-07-15

Related Papers

Abstract 7440: Characterization of the metastatic TIME via spatial transcriptomics reveals unique cellular phenotypes post anti-CSF-1R and immuno-chemotherapy

Cancer Research2026-04-03